Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Data Volume and the Need for Clinical Decision Support in Glaucoma Care.

Ophthalmology science·2026
Same author

Extraction of Glaucoma Diagnosis, Type, and Severity from Clinical Notes using Secure Cloud-based Large Language Models.

medRxiv : the preprint server for health sciences·2026
Same author

GLLaucoMed: A Secure LLM-Powered Agentic Workflow for Automated Medication Extraction from Free-Text Glaucoma Clinical Notes.

medRxiv : the preprint server for health sciences·2026
Same author

Optic Disc Fundus Images Retain Biometric Identity Signals Under Deep Learning.

Research square·2026
Same author

Development and Pilot Testing of a Mobile App Psychosocial Intervention for Psychological Distress in Individuals with Glaucoma.

medRxiv : the preprint server for health sciences·2026
Same author

Reply to Comment on "RNFL Thickness in a Population-Based Cohort: The Canadian Longitudinal Study on Aging M2M (Machine-to-Machine) Study".

American journal of ophthalmology·2026

Related Experiment Video

Updated: Aug 21, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.2K

Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies.

Robert N Weinreb1, Jason Bacharach2, Jacob W Brubaker3

  • 1Hamilton Glaucoma Center and Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|November 15, 2022
PubMed
Summary

The biodegradable bimatoprost implant for glaucoma showed variable but significant biodegradation in most patients within 12 months, offering an alternative to daily eye drops.

Keywords:
biodegradable implantdrug delivery systemintraocular injectionprostaglandin analograndomized clinical trial

More Related Videos

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.6K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.4K

Related Experiment Videos

Last Updated: Aug 21, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.2K
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.6K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.4K

Area of Science:

  • Ophthalmology
  • Drug Delivery Systems
  • Biomaterials

Background:

  • Glaucoma and ocular hypertension management often relies on daily eye drops.
  • Sustained-release drug delivery systems offer an alternative to topical medications.
  • Intracameral biodegradable implants aim to provide consistent IOP reduction.

Purpose of the Study:

  • To evaluate the biodegradation time course of an intracameral, sustained-release bimatoprost implant.
  • To assess the safety and efficacy of the bimatoprost implant compared to timolol.
  • To understand the physical changes and degradation of the implant in the anterior chamber.

Main Methods:

  • Two identically designed, randomized, phase 3 clinical trials.
  • Adults with open-angle glaucoma or ocular hypertension received 10- or 15-μg bimatoprost implants or topical timolol.
  • Implants were assessed via gonioscopy for visibility, size, and location throughout the study.

Main Results:

  • Biodegradation of the bimatoprost implant varied among patients.
  • Implants frequently swelled between 6-28 weeks, followed by accelerated biodegradation (31-52 weeks).
  • By 52 weeks, 82% of implants were absent or ≤25% of initial size; 95% by 20 months.

Conclusions:

  • Clinically significant biodegradation of the bimatoprost implant occurred in most patients by 12 months.
  • The implant's biodegradation profile is variable but predictable over time.
  • Further studies are ongoing to optimize implant re-administration timing.